Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction - 05/08/19
, Thomas G. von Lueder, MD, PhD a, Faiez Zannad, MD, PhD b, c, d, e, Patrick Rossignol, MD, PhD b, c, d, e, Kevin Duarte, MSc b, c, d, e, Tahar Chouihed, MD b, e, f, Scott D. Solomon, MD g, Kenneth Dickstein, MD, PhD h, i, Dan Atar, MD, PhD a, j, Stefan Agewall, MD, PhD a, j, Nicolas Girerd, MD, PhD b, c, d, efor the High-Risk Myocardial Infarction Database Initiative investigators
Abstract |
Background |
Reduced left ventricular ejection fraction (LVEF) after acute myocardial infarction (MI) increases risk of cardiovascular (CV) hospitalizations, but evidence regarding its association with non-CV outcome is scarce. We investigated the association between LVEF and adjudicated cause-specific hospitalizations following MI complicated with low LVEF or overt heart failure (HF).
Methods |
In an individual patient data meta-analysis of 19,740 patients from 3 large randomized trials, Fine and Gray competing risk modeling was performed to study the association between LVEF and hospitalization types.
Results |
The most common cause of hospitalization was non-CV (n = 2,368 for HF, n = 1,554 for MI, and n = 3,703 for non-CV). All types of hospitalizations significantly increased with decreasing LVEF. The absolute risk increase associated with LVEF ≪25% (vs LVEF ≫35%) was 15.5% (95% CI 13.4-17.5) for HF, 4.7% (95% CI 3.0-6.4) for MI, and 10.4% (95% CI 8.0-12.8) for non-CV hospitalization. On a relative scale, after adjusting for confounders, each 5-point decrease in LVEF was associated with an increased risk of HF (hazard ratio [HR] 1.15, 95% CI 1.12-1.18), MI (HR 1.06, 95% CI 1.03-1.10), and non-CV hospitalization (HR 1.03, 95% CI 1.01-1.05).
Conclusions |
In a high-risk population with complicated acute MI, the absolute risk increase in non-CV hospitalizations associated with LVEF ≪25% was two thirds of the absolute risk increase in HF hospitalizations and twice the absolute risk increase in MI hospitalizations. LVEF was an independent predictor of all types of hospitalization and appears as an integrative marker of sicker patient status.
Le texte complet de cet article est disponible en PDF.Plan
Vol 215
P. 83-90 - septembre 2019 Retour au numéro
Article précédent
- Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease
- Krzysztof Kuku?a, Arkadiusz Urbanowicz, Mariusz K?opotowski, Maciej D?browski, Jerzy Pr?gowski, Jacek K?dziela, Zbigniew Chmielak, Adam Witkowski, Witold Ru?y??o
- Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial
- Abhinav Sharma, Emil Hagström, Daniel M. Wojdyla, Megan L. Neely, Robert A. Harrington, Lars Wallentin, John H. Alexander, Shaun G. Goodman, Renato D. Lopes, Apixaban for Prevention of Acute Ischemic Safety Events APPRAISE-2 Steering Committee and Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?